T1	DISO 574 607	virus de inmunodeficiencia humana
#1	AnnotatorNotes T1	C0458074; Human immunodeficiency virus (HIV) status; Finding
T2	CHEM 788 802	lioprotectores
T3	DISO 609 612	VIH
#2	AnnotatorNotes T3	C0458074; Human immunodeficiency virus (HIV) status; Finding
T4	PROC 230 285	evaluar la seguridad, reactogenicidad e inmunogenicidad
T5	CHEM 290 319	candidato vacunal liofilizado
T6	DISO 330 336	cólera
#3	AnnotatorNotes T6	C0008354; Cholera; Disease or Syndrome
T7	DISO 1387 1392	VIH-2
#4	AnnotatorNotes T7	C0854094; HIV-2 infection; Disease or Syndrome
T8	DISO 537 543	cólera
#5	AnnotatorNotes T8	C0008354; Cholera; Disease or Syndrome
T9	PROC 664 675	tratamiento
#6	AnnotatorNotes T9	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T10	PROC 1345 1369	detección de anticuerpos
#7	AnnotatorNotes T10	C0430425; Procedure to identify antibody; Laboratory Procedure
T11	PROC 758 765	placebo
#8	AnnotatorNotes T11	C0032042; Placebos; Therapeutic or Preventive Procedure
T12	PROC 816 839	seguimiento ambulatorio
#9	AnnotatorNotes T12	C0589125; Follow-up in outpatient clinic; Health Care Activity
T13	DISO 847 863	eventos adversos
#10	AnnotatorNotes T13	C0877248; Adverse event; Pathologic Function
T14	CHEM 1010 1033	anticuerpos vibriocidas
#11	AnnotatorNotes T14	C0370142; Vibrio cholerae antibody; Amino Acid, Peptide, or Protein · Immunologic Factor
T15	ANAT 1041 1047	sueros
#12	AnnotatorNotes T15	C0229671; Serum; Body Substance | C0588987; Serum product; Body Substance
T16	PROC 1112 1124	inmunización
#13	AnnotatorNotes T16	C0020971; Immunization; Therapeutic or Preventive Procedure
T17	DISO 1144 1160	eventos adversos
#14	AnnotatorNotes T17	C0877248; Adverse event; Pathologic Function
T18	DISO 1187 1203	eventos adversos
#15	AnnotatorNotes T18	C0877248; Adverse event; Pathologic Function
T19	PROC 1274 1281	placebo
#16	AnnotatorNotes T19	C0032042; Placebos; Therapeutic or Preventive Procedure
T20	DISO 1288 1304	eventos adversos
#17	AnnotatorNotes T20	C0877248; Adverse event; Pathologic Function
T21	DISO 1380 1385	VIH-1
#18	AnnotatorNotes T21	C2363741; HIV-1 infection; Disease or Syndrome
T22	DISO 1394 1409	hepatitis (H) A
#19	AnnotatorNotes T22	C0019159; Hepatitis A; Disease or Syndrome
T23	CHEM 1358 1369	anticuerpos
#20	AnnotatorNotes T23	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T24	PROC 1419 1469	antígeno de superficie del virus de la hepatitis B
#21	AnnotatorNotes T24	C0201478; Hepatitis B surface antibody measurement; Laboratory Procedure
T25	DISO 1527 1543	eventos adversos
#22	AnnotatorNotes T25	C0877248; Adverse event; Pathologic Function
T26	CHEM 1663 1686	anticuerpos vibriocidas
#23	AnnotatorNotes T26	C0370142; Vibrio cholerae antibody; Amino Acid, Peptide, or Protein · Immunologic Factor
T27	PROC 1748 1755	placebo
#24	AnnotatorNotes T27	C0032042; Placebos; Therapeutic or Preventive Procedure
T28	DISO 1903 1909	cólera
#25	AnnotatorNotes T28	C0008354; Cholera; Disease or Syndrome
T29	CHEM 19 25	vacuna
#26	AnnotatorNotes T29	C0042210; Vaccines; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T30	PROC 156 223	ensayo clínico controlado con placebo, aleatorizado y a doble ciego
#27	AnnotatorNotes T30	C0599724; placebo controlled study; Research Activity + C0013072; Double-Blind Method; Research Activity + C0206034; Clinical Trials, Randomized; Research Activity
T31	CHEM 711 728	candidato vacunal
T32	CHEM 1242 1248	vacuna
#28	AnnotatorNotes T32	C0042210; Vaccines; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T33	DISO 1411 1413	HC
#29	AnnotatorNotes T33	C0019196; Hepatitis C; Disease or Syndrome
T34	DISO 1458 1469	hepatitis B
#30	AnnotatorNotes T34	C0019163; Hepatitis B; Disease or Syndrome
T35	CHEM 1549 1561	cepa vacunal
T36	CHEM 1619 1625	vacuna
#31	AnnotatorNotes T36	C0042210; Vaccines; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T37	CHEM 1705 1711	vacuna
#32	AnnotatorNotes T37	C0042210; Vaccines; Immunologic Factor · Amino Acid, Peptide, or Protein · Pharmacologic Substance
T38	CHEM 1830 1847	candidato vacunal
T39	Dose 1 12	Dosis única
T41	Route 26 30	oral
#33	AnnotatorNotes T41	C1527415; Oral Route of Drug administration; Functional Concept
T42	LIVB 63 78	Vibrio cholerae
#34	AnnotatorNotes T42	C0042629; Vibrio cholerae; Bacterium
T43	LIVB 107 126	voluntarios adultos
#35	AnnotatorNotes T43	C0020155; Human Volunteers; Population Group + C0001675; Adult; Age Group
T45	LIVB 369 380	V. cholerae
#36	AnnotatorNotes T45	C0042629; Vibrio cholerae; Bacterium
T46	LIVB 417 443	voluntarios de ambos sexos
#37	AnnotatorNotes T46	C0020155; Human Volunteers; Population Group + C0025266; Male population group; Population Group + C0043210; Woman; Population Group
T47	Age 466 484	entre 18 y 50 años
T51	LIVB 640 647	sujetos
#38	AnnotatorNotes T51	C0681850; Study Subject; Group
T52	Dose 694 706	2 x 10 9 UFC
T53	Route 686 690	oral
#39	AnnotatorNotes T53	C1527415; Oral Route of Drug administration; Functional Concept
T54	Dose 744 753	una dosis
T55	Duration 872 879	30 días
T56	PHYS 885 901	respuesta inmune
#40	AnnotatorNotes T56	C0020964; Immune response; Organ or Tissue Function
T58	Neg_cue 1127 1129	No
T60	LIVB 1446 1469	virus de la hepatitis B
#41	AnnotatorNotes T60	C0019169; hepatitis B virus; Virus
T61	LIVB 1488 1497	helmintos
#42	AnnotatorNotes T61	C0018893; Helminths; Eukaryote
T63	LIVB 1589 1600	voluntarios
#43	AnnotatorNotes T63	C0020155; Human Volunteers; Population Group
T69	Duration 1078 1094	los 14 y 21 días
T70	Duration 1630 1641	los 14 días
T71	Duration 1797 1808	los 21 días
T48	LIVB 1055 1066	voluntaries
#44	AnnotatorNotes T48	C0020155; Human Volunteers; Population Group
T40	LIVB 343 347	cepa
#45	AnnotatorNotes T40	C1518614; Organism Strain; Organism
T44	LIVB 37 41	cepa
#46	AnnotatorNotes T44	C1518614; Organism Strain; Organism
T49	LIVB 1549 1553	cepa
#47	AnnotatorNotes T49	C1518614; Organism Strain; Organism
T50	Neg_cue 1498 1500	no
T57	Dose 676 685	una dosis
T59	Quantifier_or_Qualifier 42 55	viva atenuada
T62	Quantifier_or_Qualifier 348 361	viva atenuada
T64	Quantifier_or_Qualifier 459 464	sanos
#48	AnnotatorNotes T64	C3898900; Healthy; Qualitative Concept
T65	Quantifier_or_Qualifier 729 732	638
T66	Observation 953 967	seroconversión
#49	AnnotatorNotes T66	C4042908; Seroconversion; Finding
T68	CONC 973 1000	media geométrica del título
#50	AnnotatorNotes T68	C2986759; Geometric Mean; Quantitative Concept + C0475208; Titer; Quantitative Concept
T72	CONC 1002 1005	MGT
#51	AnnotatorNotes T72	C2986759; Geometric Mean; Quantitative Concept + C0475208; Titer; Quantitative Concept
T73	Quantifier_or_Qualifier 1161 1167	graves
T74	CONC 1656 1659	MGT
#52	AnnotatorNotes T74	C2986759; Geometric Mean; Quantitative Concept + C0475208; Titer; Quantitative Concept
T75	Observation 1765 1779	seroconversión
#53	AnnotatorNotes T75	C4042908; Seroconversion; Finding
T76	Quantifier_or_Qualifier 1848 1851	638
T77	Quantifier_or_Qualifier 56 59	638
T78	Quantifier_or_Qualifier 362 365	638
T79	CONC 554 569	seroprevalencia
#54	AnnotatorNotes T79	C0600367; Seroprevalence; Quantitative Concept
A1	Population_data T43 Age
A2	Assertion T17 Negated
A3	Assertion T25 Negated
R1	Has_Dose_or_Strength Arg1:T29 Arg2:T39
R2	Has_Route_or_Mode Arg1:T29 Arg2:T41
R3	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T59
R4	Experiences Arg1:T43 Arg2:T29
R5	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T62
R6	Causes Arg1:T45 Arg2:T6
R7	Has_Age Arg1:T46 Arg2:T47
R8	Has_Quantifier_or_Qualifier Arg1:T46 Arg2:T64
R10	Experiences Arg1:T51 Arg2:T9
R11	Used_for Arg1:T31 Arg2:T9
R12	Has_Dose_or_Strength Arg1:T31 Arg2:T52
R13	Has_Dose_or_Strength Arg1:T31 Arg2:T57
R14	Has_Route_or_Mode Arg1:T31 Arg2:T53
R15	Has_Quantifier_or_Qualifier Arg1:T31 Arg2:T65
R16	Used_for Arg1:T2 Arg2:T11
R18	Experiences Arg1:T51 Arg2:T11
R19	Has_Duration_or_Interval Arg1:T12 Arg2:T55
R20	Experiences Arg1:T48 Arg2:T14
R21	Experiences Arg1:T48 Arg2:T56
R22	Experiences Arg1:T48 Arg2:T66
R24	After Arg1:T68 Arg2:T69
R25	After Arg1:T72 Arg2:T69
R26	Negation Arg1:T58 Arg2:T17
R27	Before Arg1:T16 Arg2:T69
R29	Before Arg1:T68 Arg2:T16
R31	Before Arg1:T72 Arg2:T16
R32	Has_Quantifier_or_Qualifier Arg1:T17 Arg2:T73
R33	Causes Arg1:T32 Arg2:T18
R34	Causes Arg1:T60 Arg2:T34
R35	Negation Arg1:T50 Arg2:T25
R36	Experiences Arg1:T63 Arg2:T36
R37	Overlap Arg1:T75 Arg2:T71
R38	Overlap Arg1:T74 Arg2:T70
R40	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T76
R17	Has_Dose_or_Strength Arg1:T2 Arg2:T54
R41	Causes Arg1:T19 Arg2:T18
R42	Has_Quantifier_or_Qualifier Arg1:T44 Arg2:T77
R43	Has_Quantifier_or_Qualifier Arg1:T40 Arg2:T78
R9	After Arg1:T66 Arg2:T69
R23	After Arg1:T66 Arg2:T16
R28	Before Arg1:T37 Arg2:T75
T67	DISO 252 267	reactogenicidad
#55	AnnotatorNotes T67	C5552969; Reactogenicity; Pathologic Function
R30	Causes Arg1:T5 Arg2:T67	
#56	AnnotatorNotes T73	C1547227; Severe -Severity of Illness Code; Intellectual Product
A4	Experiencer T43 Patient
A5	Experiencer T46 Patient
A6	Experiencer T51 Patient
A7	Experiencer T48 Patient
A8	Experiencer T63 Patient
